Case type Product Liability

Roundup

Diagnosed with non-Hodgkin lymphoma after using Roundup? Tell us what happened.

Thousands of people have filed lawsuits alleging that exposure to Roundup and other glyphosate-based herbicides contributed to non-Hodgkin lymphoma, and that users were never warned of the alleged risk. A diagnosis on its own does not decide whether there is a claim — exposure history, timing, the pathology and the applicable law all matter, and sorting that out is our half of it rather than yours. The federal cases are coordinated before one judge5, so we review these claims for people anywhere in the country. Start with a free case review. No attorney’s fee unless we recover, and nothing owed for asking.

People usually call us with a working life rather than a legal theory: the years of spraying fence lines, the decade of Saturdays on the driveway, and then a biopsy and a word nobody in the family had said out loud before. Whether that history adds up to a claim turns on the exposure, the pathology and the dates — and finding that out is our work, not yours.

Roundup and glyphosate

Roundup is a widely used herbicide. Its primary active ingredient is glyphosate, a broad-spectrum herbicide used to control weeds and grasses in agricultural, commercial and residential settings.

Glyphosate has been registered as a pesticide in the United States since 19742. It has been used on farms, on landscaping projects, along rights-of-way, in parks, on commercial properties and in residential yards.

People who may have experienced repeated direct exposure include:

  • Farmers and agricultural workers
  • Landscapers and groundskeepers
  • Nursery and horticultural workers
  • Maintenance workers
  • Property owners
  • Home gardeners
  • People who regularly mixed or applied Roundup
  • People who worked around areas where Roundup was routinely applied

The amount, the frequency and the manner of exposure can vary significantly from one person to the next, which is why an exposure history is read rather than counted.

Why there are Roundup lawsuits

Roundup litigation centers on allegations that exposure to glyphosate-based herbicides can contribute to the development of non-Hodgkin lymphoma, and that users were not adequately warned about the alleged cancer risk.

The scientific and regulatory history matters here, because major organizations have reached different conclusions about the same chemical.

What the record actually says

IARC, 2015
The International Agency for Research on Cancer, the cancer research agency of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” (Group 2A), reporting limited evidence of carcinogenicity in humans for non-Hodgkin lymphoma and sufficient evidence of carcinogenicity in experimental animals1.
EPA, previously
The U.S. Environmental Protection Agency reached a different conclusion. Its previous human-health assessment found that glyphosate was not likely to be carcinogenic to humans when used according to its label2.
EPA, now
EPA is reevaluating glyphosate under registration review. In August 2026 the agency published the results of a systematic search of the published literature to inform an updated human-health risk assessment, which it has targeted for completion in late 20263.
What none of it settles
A scientific classification, a regulatory determination and an individual lawsuit are three different things. None of them, on its own, establishes that glyphosate caused a particular person’s illness.

That last line is not a lawyer hedging. It is the reason these cases are decided on one person’s exposure history and one person’s pathology rather than on a headline.

A classification is not a diagnosis, and a regulatory finding is not a verdict.

Roundup litigation: how we got here

The chronology behind the current cases

  1. 1974

    Glyphosate is first registered for pesticide use in the United States2.

  2. 2015

    IARC classifies glyphosate as “probably carcinogenic to humans,” citing limited evidence in humans for non-Hodgkin lymphoma1.

  3. 2016

    Federal Roundup lawsuits are consolidated for coordinated pretrial proceedings in multidistrict litigation — In re: Roundup Products Liability Litigation, MDL No. 2741, in the U.S. District Court for the Northern District of California5.

  4. 2018

    An update of the Agricultural Health Study, a large prospective cohort of licensed pesticide applicators, reports no apparent association between glyphosate and lymphoid malignancies overall, including non-Hodgkin lymphoma and its subtypes7.

  5. 2020

    EPA issues an interim registration review decision concluding that glyphosate is not likely to be carcinogenic to humans.

  6. 2022

    The Ninth Circuit vacates the human-health portion of EPA’s interim decision4. EPA subsequently withdraws the interim registration review decision while continuing its review of glyphosate.

  7. June 2026

    In Monsanto Co. v. Durnell, the Supreme Court holds that the Federal Insecticide, Fungicide, and Rodenticide Act expressly preempts a state-law failure-to-warn claim that would have required a cancer warning on Roundup’s label6. The decision changes the legal ground under a warning claim, and what it means for any particular case depends on that case.

  8. 2026

    EPA continues its registration review and is updating its glyphosate human-health risk assessment, including its evaluation of carcinogenic potential3. A proposed nationwide class settlement is pending in Missouri state court, with a fairness hearing set for September 14, 20269.

A chronology, not a schedule. Where any of it leaves an individual claim is a question about that claim, and it is the question a case review is for.

Non-Hodgkin lymphoma and Roundup

Non-Hodgkin lymphoma is not a single disease. It is a group of cancers that begin in white blood cells called lymphocytes, which are part of the body’s immune system8.

There are many different forms of NHL, and they can behave differently, require different treatments and affect people differently. The Roundup litigation has focused primarily on whether exposure to glyphosate-based herbicides may be associated with an increased risk of NHL.

Researchers have studied the question for years, and the evidence is not uniform. Some epidemiological studies and analyses have reported associations involving glyphosate exposure and NHL or particular NHL subtypes, while other major research — including findings from the Agricultural Health Study — has not found an association between glyphosate and NHL overall7.

That distinction matters, and it is worth stating plainly: an association identified in a study does not establish that Roundup caused an individual person’s cancer. Which is why the first thing we ask for is not a study. It is a pathology report.

Who may be considered for a Roundup claim review

Every potential claim requires an individual review. Our current screening criteria weigh several things together — exposure history, diagnosis and timing — and they are set out here so you know what we are going to ask, not so you can rule yourself out. That part is our job, and we would rather do it on the phone than leave you guessing. When in doubt, call.

What the current screening criteria look at

Direct exposure
The injured person must have experienced direct exposure to Roundup — spraying it, handling or mixing it, physical contact while using it, or contact involving the eyes, nose or mouth. Under the current criteria that exposure history generally involves at least 30 separate Roundup exposures.
A qualifying diagnosis
The injured person must have been diagnosed with a qualifying form of non-Hodgkin lymphoma. NHL has many subtypes, so the exact diagnosis in the chart is part of the review rather than a detail.
The gap between them
Timing matters. Under the current criteria the NHL diagnosis must have come at least one year after the person’s first Roundup use.
Date of diagnosis
Screening generally considers diagnoses made in 2005 or later. An earlier diagnosis may still be reviewed where a pathology report is available.
Age at diagnosis
Under the current criteria the injured person must have been 79 years old or younger when the NHL was diagnosed.
Family history
A parent or sibling diagnosed with non-Hodgkin lymphoma may affect whether a claim meets the current criteria. Tell us either way rather than deciding for us.
HIV or AIDS before the NHL
A diagnosis of HIV or AIDS before the person’s NHL diagnosis may affect whether a claim meets the current criteria.

None of these are legal tests, and they are not the law of any state. They are the facts that let us tell you quickly and honestly whether there is something here.

Meeting every criterion above does not mean you have a case, and nobody can honestly tell you that you do until someone has read the records. Missing one does not settle it either — the history as a family remembers it and the history as the chart records it are not always the same, and finding out which you have costs nothing.

Information that can help with a Roundup review

You do not need to know every detail before contacting us. If you do not have a document, say so and tell us what you know instead.

  • Approximate years Roundup was used
  • How frequently it was used
  • How it was applied
  • Whether the injured person personally sprayed or handled it
  • Where the exposure occurred
  • Approximate date of first exposure
  • The NHL diagnosis and subtype, if known
  • Date of diagnosis, and age at diagnosis
  • Name of the diagnosing hospital or physician
  • Pathology or biopsy information
  • Treatment history
  • Relevant family medical history

Where records have to be requested, these are the documents that usually do the work — and locating older ones takes time, which is the main reason we start on them early:

  • Pathology reports
  • Biopsy reports
  • Oncology records
  • Hematology records
  • Hospital records
  • Treatment records
  • Imaging reports
  • Laboratory results
  • Records confirming the date and type of diagnosis

What happens after you contact CBW Law

Five steps, in this order

  1. Tell us what happened

    Start with the Roundup exposure and the diagnosis. Plain language is fine; so is an incomplete chronology.

  2. We review the basic information

    Our team looks at the exposure history, the frequency, the diagnosis, the timing between them and the rest of the screening information.

  3. We identify what is missing

    That may be a medical provider, pathology information, or detail about how and when Roundup was used.

  4. Medical documentation may be requested

    Records can confirm the diagnosis, the subtype and the relevant dates. This is the stage the case usually waits on, and the stage we do rather than you.

  5. The information is reviewed

    Meeting initial screening criteria does not guarantee that a claim can be filed or that compensation will be recovered. The facts and the applicable law have to be reviewed individually, and we will tell you plainly what we find.

Plain English

Medical, Health & Insurance

A Roundup review needs considerably more than confirmation that someone has cancer. It needs the exact diagnosis, the subtype, the date and the treatment history — and all of that arrives in two vocabularies, neither of them yours: the clinical language in the chart, and the coverage language in the letters from the health plan. Here is what the words mean, so the paperwork is readable before it becomes decisive.

The diagnosis, in plain English

Non-Hodgkin lymphoma (NHL)
A broad category of cancers involving lymphocytes, a type of white blood cell. It is a group of diseases rather than one, which is why the subtype in the chart matters.
Lymphocyte
A white blood cell that is part of the immune system. The major types include B cells and T cells.
B-cell lymphoma
A category of NHL involving B lymphocytes. Many NHL diagnoses are B-cell lymphomas.
Diffuse large B-cell lymphoma (DLBCL)
A type of B-cell non-Hodgkin lymphoma.
Follicular lymphoma
A type of B-cell non-Hodgkin lymphoma.

How a diagnosis is documented

Biopsy
A procedure in which tissue or cells are removed and examined to help establish a diagnosis.
Pathology report
A medical report containing the findings from examination of tissue, cells or other specimens. Pathology documentation is often what confirms the exact type of lymphoma diagnosed, which is why we ask about it first.
Oncology
The medical specialty involving the diagnosis and treatment of cancer.
Hematology
The medical specialty involving blood and blood-related diseases. Some physicians specialize in both hematology and oncology.
Date of diagnosis
The date the chart records the diagnosis being made, which is not always the date a person remembers being told. Screening runs on the recorded date.

Records, insurance and billing

Authorization for release of records
The signed form that lets a provider send records to someone else. Expect to sign more than one, because facilities and physician groups usually hold separate files.
Explanation of benefits (EOB)
Not a bill. It is the health plan’s account of what was billed, what it allowed, what it paid and what it says is still owed. Keep every one of them — together they map where treatment happened.
Prior authorization
A plan’s approval before it will pay for treatment. A denial at this stage is appealable, and the appeal file is worth keeping.
Subrogation and liens
A health plan or program that paid for treatment may assert a right to be repaid out of any recovery. Finding those claims and negotiating them down is part of the case rather than an afterthought.

Educational only. These are plain-language summaries of words that turn up in charts, letters and bills — not clinical definitions, not medical advice, not a diagnosis of anyone, and not a description of what any particular policy covers. For what a diagnosis means, ask the clinician who made it. For what a plan covers, read the plan, and bring it to us if it is not clear.

Questions

Frequently asked Roundup questions

The questions callers actually open with, answered the way we would answer them on the phone.

What is Roundup?

Roundup is a brand of herbicide. Many Roundup products have contained glyphosate as an active ingredient.

What is glyphosate?

Glyphosate is a broad-spectrum herbicide used to control weeds and grasses. It is used in agricultural, commercial and residential settings, and it has been registered as a pesticide in the United States since 1974.

Does glyphosate cause non-Hodgkin lymphoma?

Scientific and regulatory organizations have reached different conclusions. IARC classifies glyphosate as probably carcinogenic to humans and found limited evidence of carcinogenicity in humans for non-Hodgkin lymphoma. EPA’s previous assessment concluded that glyphosate was not likely to be carcinogenic to humans, and EPA is currently updating its human-health and carcinogenicity assessment.

Neither conclusion establishes whether Roundup caused an individual person’s NHL. That question is answered case by case, on the exposure history and the medical record.

What cancer is involved in the Roundup litigation?

The litigation has primarily involved allegations concerning non-Hodgkin lymphoma.

NHL includes multiple subtypes, so determining the exact diagnosis can matter during a claim review.

How much Roundup exposure is considered during screening?

Our current screening criteria generally require direct exposure on 30 or more occasions.

Frequency is only one part of it. How the product was used, when exposure began, the diagnosis and the gap between exposure and diagnosis are all part of the same review.

Does getting Roundup on my skin count as exposure?

Direct handling, spraying and physical contact with Roundup can all be relevant to an exposure history. The circumstances and the frequency of that exposure still have to be reviewed.

What if I used Roundup at home instead of at work?

Exposure is not limited to agricultural employment. Residential and other direct use can be reviewed as part of the exposure history.

How long after Roundup exposure must NHL have been diagnosed?

Under our current screening criteria, the NHL diagnosis must have come at least one year after the person’s first Roundup use.

What if I was diagnosed before 2005?

Current screening generally focuses on diagnoses from 2005 forward. An earlier diagnosis may still be reviewed individually, particularly where supporting pathology documentation exists.

Can a family contact CBW Law if the person who used Roundup has died?

Yes. Additional information will be needed, including the date and cause of death and potentially a death certificate.

Other requirements and deadlines may also apply, and they can depend on where the claim belongs. That is one of the first things we check.

Why are medical records important?

Records confirm the things a claim is built on — the diagnosis, the NHL subtype, the date of diagnosis and the treatment history. What a family remembers and what the chart recorded are not always the same, and the chart is what the case runs on.

Do I need my medical records before contacting CBW Law?

No. You can begin by telling us what you know. If additional documentation is needed, the records process can be discussed after the initial review — and collecting it is our job.

Does meeting the screening criteria mean I have a lawsuit?

No. Screening criteria help determine whether further review is appropriate. They do not establish that Roundup caused an illness, that a viable legal claim exists, or that compensation will be recovered.

It also means we say no when the claim is not there, and tell you why. Taking a case we cannot prove does nobody any favors.

This page is general information about how Roundup claims work. It is not legal advice, it does not create an attorney-client relationship, and it is not medical advice about anyone’s diagnosis or treatment. If something here sounds like your history, the useful next step is a conversation about the facts.

Keep reading

Roundup resources

Places to keep researching away from any law firm’s website: the regulator that decides what a pesticide label says, the agency that classified the chemical, the court handling the coordinated federal cases, and the court-authorized website for the pending class settlement.

Regulators

EPA — Glyphosate

The agency’s own page on glyphosate: its registration, its assessments and where the current registration review stands.

Regulators

Glyphosate registration review docket, EPA-HQ-OPP-2009-0361

The public docket on regulations.gov, including the August 2026 literature search and the comment period that closes September 24, 2026.

Science

IARC Monographs Volume 112

The World Health Organization agency’s 2015 evaluation of glyphosate and four other organophosphate insecticides, in full.

Courts

MDL 2741 case page, U.S. District Court for the Northern District of California

The court’s own page for the coordinated federal proceeding: the docket, the pretrial orders and the schedule.

Courts

Weed Killer Class Settlement — official settlement website

The court-authorized site for the proposed class settlement in *Randall King, et al. v. Monsanto Company*, with the notice, the settlement agreement and the hearing schedule.

Public health

National Cancer Institute — adult non-Hodgkin lymphoma treatment (PDQ)

The federal cancer institute’s plain-language summary of NHL, its subtypes and how it is treated.

Science

Agricultural Health Study

The long-running federal cohort study of licensed pesticide applicators and their families in Iowa and North Carolina.

Placeholders become links once the organization and the address have both been verified — this page will not point you at an address nobody checked.

Apparatus

Sources & Cited Articles

Different from Resources above. Resources are places to keep reading; this is the source material behind any factual, legal, medical or statistical claim the page makes, numbered so a marker in the text can point at one.

  1. IARC Monographs Volume 112: Some Organophosphate Insecticides and HerbicidesInternational Agency for Research on Cancer, World Health Organization · IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (2017)The evaluation that classified glyphosate in Group 2A, “probably carcinogenic to humans,” on limited evidence in humans for non-Hodgkin lymphoma and sufficient evidence in experimental animals. Cited for the classification and for what IARC said the evidence was.
  2. GlyphosateU.S. Environmental Protection Agency · Ingredients Used in Pesticide ProductsThe agency’s own page on glyphosate. Cited for the 1974 registration, for EPA’s previous conclusion that glyphosate is not likely to be carcinogenic to humans when used according to label directions, and for the existence of the ongoing registration review.
  3. Glyphosate Open Literature Search To Inform Human Health Risk Assessment; Notice of AvailabilityU.S. Environmental Protection Agency · 91 Fed. Reg. 54870 (Aug. 25, 2026); Docket EPA-HQ-OPP-2009-0361“This open literature search is intended to inform the hazard assessment for the upcoming updated glyphosate human health risk assessment, currently scheduled to be completed in late 2026.” Cited for the August 2026 search, the updated assessment and the September 24, 2026 comment deadline.
  4. Natural Resources Defense Council v. U.S. Environmental Protection Agency, 38 F.4th 34U.S. Court of Appeals for the Ninth Circuit · No. 20-70787 (June 17, 2022)The decision vacating the human-health portion of EPA’s 2020 interim registration review decision on glyphosate. Cited for the vacatur, not for anything about any individual case.
  5. In re: Roundup Products Liability Litigation — MDL No. 2741U.S. District Court for the Northern District of California · Case No. 3:16-md-02741-VCThe court’s own case page for the coordinated federal proceeding, before U.S. District Judge Vince Chhabria. Cited for the existence, name, court and 2016 consolidation of the proceeding.
  6. Monsanto Co. v. Durnell, 609 U.S. ___ (2026)Supreme Court of the United States · No. 24-1068, decided June 25, 2026 (slip opinion)“FIFRA expressly preempts Durnell’s state-law failure-to-warn claim because the claim would require Monsanto to add a cancer warning to Roundup’s label.” Cited for the holding and the date. The Court did not reach the implied-preemption argument (slip op., at 14 n. 7).
  7. Glyphosate Use and Cancer Incidence in the Agricultural Health StudyAndreotti G, Koutros S, Hofmann JN, et al. · Journal of the National Cancer Institute, 110(5):509–516 (May 1, 2018)“No association was apparent between glyphosate and any solid tumors or lymphoid malignancies overall, including NHL and its subtypes.” Cited for that finding in this cohort, and for nothing beyond it.
  8. Adult Non-Hodgkin Lymphoma Treatment (PDQ) — Patient VersionNational Cancer Institute · National Institutes of HealthThe federal cancer institute’s summary of non-Hodgkin lymphoma. Cited for the description of NHL as a group of cancers that begin in lymphocytes.
  9. Randall King, et al. v. Monsanto Company — Weed Killer Class Settlement22nd Judicial Circuit Court, City of St. Louis, Missouri · No. 2622-CC00325; court-authorized settlement websiteThe official notice site for the proposed class settlement. Cited for the case, the court and the September 14, 2026 fairness hearing — not for any prediction about whether the settlement is approved.

Accountability

Reviewed by

Craig Weiss, founder and managing attorney of CBW Law Firm

Craig Weiss

Managing Attorney · CBW Law

View full profile →

Attorney advertising. The content of this website may be considered attorney advertising under the rules of certain jurisdictions. The information on this website is for general information purposes only and should not be taken as legal advice for any individual case or situation. Viewing this site does not create an attorney-client relationship. Prior results do not guarantee a similar outcome. Statutes, regulations and case law change, and the law differs from state to state.